纯度 | >95%SDS-PAGE. |
种属 | Human |
靶点 | BTN1A1 |
Uniprot No | Q13410 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 27-242aa |
氨基酸序列 | APFDVIGPPEPILAVVGEDAELPCRLSPNASAEHLELRWFRKKVSPAVLV HRDGREQEAEQMPEYRGRATLVQDGIAKGRVALRIRGVRVSDDGEYTCFF REDGSYEEALVHLKVAALGSDPHISMQVQENGEICLECTSVGWYPEPQVQ WRTSKGEKFPSTSESRNPDEEGLFTVAASVIIRDTSAKNVSCYIQNLLLG QEKKVEISIPASSLPRVDHHHHHH |
预测分子量 | 25 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BTN1A1重组蛋白的3篇参考文献的简要信息:
1. **文献名称**:*"Butyrophilin 1A1: A Structural Component of Milk Lipid Droplets in Mammary Epithelium"*
**作者**:Ogg, S.L., et al.
**摘要**:该研究通过重组BTN1A1蛋白,揭示了其在乳腺上皮细胞中与乳脂肪球膜形成的关键作用,证实其通过调控脂质分泌参与泌乳过程。
2. **文献名称**:*"Crystal Structure of the Extracellular Domain of Human BTN1A1 and Its Interaction with Xanthine Oxidase"*
**作者**:Ishii, T., et al.
**摘要**:利用重组BTN1A1蛋白进行X射线晶体学分析,解析其胞外域结构,并发现其与黄嘌呤氧化酶的特异性结合,提示其在氧化代谢中的潜在功能。
3. **文献名称**:*"BTN1A1 Regulates γδ T Cell Activation in Inflammatory Responses via Recombinant Protein-Mediated Signaling"*
**作者**:Vantourout, P., et al.
**摘要**:通过体外实验发现重组BTN1A1蛋白能够抑制γδ T细胞的过度活化,表明其在炎症和自身免疫疾病中的免疫调节作用。
4. **文献名称**:*"Recombinant BTN1A1 as a Potential Biomarker in Breast Cancer Immunotherapy"*
**作者**:Wang, Y., et al.
**摘要**:研究利用重组BTN1A1蛋白验证其在乳腺癌细胞中的高表达,并探讨其作为免疫检查点分子在肿瘤微环境中的治疗潜力。
(注:以上文献为示例,实际引用需根据具体研究核实。)
**Background of BTN1A1 Recombinant Protein**
Butyrophilin subfamily 1 member A1 (BTN1A1) is a transmembrane glycoprotein belonging to the immunoglobulin superfamily, primarily expressed in secretory epithelial cells, notably in mammary glands during lactation. It plays a critical role in lipid droplet formation and milk secretion by interacting with xanthine oxidoreductase and other proteins during the assembly of milk fat globules. Beyond its physiological function, BTN1A1 has garnered attention for its immunomodulatory properties. Structurally, it shares homology with B7 family co-stimulatory molecules, suggesting involvement in T-cell regulation and immune tolerance.
Recombinant BTN1A1 protein is engineered using expression systems (e.g., mammalian or bacterial cells) to produce soluble forms of the extracellular domain, retaining functional epitopes for research or therapeutic applications. Its production enables studies on molecular interactions, such as binding to ligands like dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) or modulating immune checkpoints.
Research highlights BTN1A1's dual role: while it supports lactation, dysregulation is linked to autoimmune diseases and cancer. For instance, BTN1A1 may suppress anti-tumor T-cell responses in certain cancers, positioning it as a potential target for immunotherapy. Additionally, its involvement in metabolic pathways and lipid metabolism disorders underscores broader biomedical relevance.
Current challenges include elucidating precise signaling mechanisms and optimizing recombinant protein stability for clinical use. Advances in structural biology and protein engineering continue to drive its application in diagnostics, antibody development, and therapeutic strategies targeting immune or metabolic diseases.
×